Business
Outlook Therapeutics Appoints Laura Cantrell as Vice President of Corporate Strategy and Business Development
ISELIN, N.J., Jan. 06, 2026 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of retina diseases, today announced it has appointed Laura Cantrell as Vice President of Corporate Strategy and Business Development. “We are very pleased to welcome Laura to Outlook Therapeutics at such a pivotal time in our evolution,” said Bob Jahr, Chief Executive Officer of Outlook Therapeutics. “La
About this update from Outlook Therapeutics, Inc.
[{"type":"image","alt":"Outlook Therapeutics, Inc.","displaySize":"","headline":null,"caption":"Outlook Therapeutics, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":80,"url":"https://media.zenfs.com/en/globenewswire.com/036f630f46be050c02b981afef3ca9e4"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/qNsjgbA2tq9jniYix8cXEg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTExMjtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/036f630f46be050c02b981afef3ca9e4","width":300,"height":80}},"lazy":false},{"type":"text","content":"ISELIN, N.J., Jan. 06, 2026 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of retina diseases, today announced it has appointed Laura Cantrell as Vice President of Corporate Strategy and Business Development.","length":328,"tagName":"p"},{"type":"image","alt":"Vice President of Corporate Strategy and Business Development","displaySize":"","headline":null,"caption":"Vice President of Corporate Strategy and Business Development","className":"","disableSlideshowImg":false,"size":{"original":{"width":499,"height":624,"url":"https://media.zenfs.com/en/globenewswire.com/4a13311d31727af2a0421e64f28692f4"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/bZxA20NtMWv5WGwyjGOV8g--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTEyMDA7Y2Y9d2VicA--/https://media.zenfs.com/en/globenewswire.com/4a13311d31727af2a0421e64f28692f4","width":499,"height":624}}},{"type":"text","content":"","length":0,"tagName":"p"},{"type":"text","content":"“We are very pleased to welcome Laura to Outlook Therapeutics at such a pivotal time in our evolution,” said Bob Jahr, Chief Executive Officer of Outlook Therapeutics. “Laura’s two decades of global biotechnology experience spanning corporate strategy, business development and portfolio leadership, and her proven ability to identify, evaluate and execute high-value opportunities, will be instrumental as we advance our mission to deliver a differentiated ophthalmic formulation of bevacizumab and pursue opportunities to maximize long-term shareholder value.”","length":562,"tagName":"p"},{"type":"text","content":"In her role as Vice President of Corporate Strategy and Business Development, Ms. Cantrell will be responsible for leading Outlook Therapeutics’ business development s...